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Aim. To investigate changes in pro-infl ammatory status of laboratory rats after introduction of antiviral 
substances with interferon-inducing action: 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline 
and tilorone. Methods. MCP-1 content, blood leukocyte counts and functional activity of phagocytes 
were measures using fl ow cytometry techniques. Complement content was determined in microtest based 
upon hemolysis of sensitized erythrocytes. Results. Both oral and intraperitoneal applications of the 
substances were characterized by an elevation in monocytic counts, potentiated metabolic reserve of 
phagocytic cells, increased MCP-1 and complement content in serum. In contrast to tilorone, after intro-
duction of 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline substantial raise in circulating neu-
trophil counts and their phagocytic activity was not determined, while  MCP-1 and complement re-
sponses were signifi cantly lower compared to reference substance. Conclusion. Although both substanc-
es are IFN-inducers with pluripotent immunostimulatory action, the tested derivative was characterized 
by a less pronounced elevation of complement activity, MCP-1 content and neutrophil counts. This im-
plies that application of 6-(2-morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline can strengthen innate 
antiviral resistance with minimized risks of potential autoimmunological adverse effects.
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Introduction
Indolo[2,3-b]quinoxalines belong to a group of low 
molecular substances with a tetracyclic heteroaromat-
ic core. A wide range of biological activity has been 
reported for different derivatives of this group, incud-
ing the anti-infl ammatory, anti-cancerogenic, antifun-
gal effects, and in case of planar confi guration – the 
antiviral action and antitumor activity. In recent years 
we have searched for new antiviral substances among 
several newly-synthesized and previously known in-
doloquinoxalines. One of them – 6-(2-morpholin-4-
yl-ethyl)-6H-indolo[2,3-b]quinoxaline (hereinafter – 
S1) – has demonstrated the low toxicity, prolonged 
interferon (IFN) induction in vivo, antiviral activity in 
vitro in both prophylactic and therapeutic application 
schemes, as well as an ability to potentiate the func-
tional activity of murine peritoneal cells [1,2]. Such 
spectrum of biological properties allowed us to con-
sider S1 an immunomodulating substance. To further 
characterize the compound it was expedient to exam-
ine in more detail the changes caused by it in the im-
mune system of laboratory animals, with particular 
focus on the pro-infl ammatory biomarkers. Tilorone 
hydrochloride, a potent IFN-inducer in rodents, was 
chosen as a reference drug.
Materials and Methods
Substances and dosage
S1 and tilorone were kindly provided by Dr Sergey 
Lyakhov (Department of Medical Chemistry, A.V. Bo-
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gatsky Physico-Chemical Institute, NAS of Uk rai-
ne). The substances were administered orally and 
in traperitoneally (i.p.) as solutions in sterile water 
according to the conventional methods. The optimal 
doses were determined in the preliminary studies of 
IFN-induction and were as follows: for tilorone – 
125 mg/kg orally, 12.5 mg/kg i.p.; for S1 – 60 mg/kg 
orally, 10 mg/kg i.p. An additional 30 mg/kg dose 
was used for the oral administration of S1, since it 
was able to induce IFN in a wider concentration 
range than the reference drug.
Animals and sampling 
To evaluate the effect of studied substances upon the 
immune system, the changes in the following pa ra-
meters were measured: immune cell counts in cir cu-
lating blood, phagocytic and metabolic activity of 
neutrophils and monocytes, complement hemolytic 
activity, levels of monocyte chemotactic protein-1 
(MCP-1). The experiment was performed on 40-day 
old male Wistar rats weighing 130–170 g. Group 
formation and marking of animals were held for 2 
days prior to the substance administration in order to 
minimize the stress. The animals were kept in large 
cages with free access to water and standard diet. 
Handling procedures were conducted according to 
European Convention for the Protection of Vertebrate 
Animals (Strasbourg, 2006). Each group consisted 
of 7–10 rats.
The blood samples were collected from the ca-
rotid arteries on I, III, VII and X day after the sub-
stances administration. Part of the blood, not less 
than 3 ml, was gathered into tubes with sodium hep-
arin («Vacuette», Austria); remaining blood was col-
lected in the centrifuge tubes for serum. Purifi ed se-
rum was frozen within 30 minutes after the blood 
collection and stored at –20 °C. 
Measurement techniques 
The numbers of lymphocytes, monocytes and granu-
locytes were measured relatively to Flow-Count 
standardized fl uorospheres using a EPICS XL fl ow 
cytometer (Beckman Coulter). Preliminary staining 
of monocytes with HIS48 antibody (BD PharMin-
gen) was performed to distinguish them from lym-
phocytic pool, whereas granulocytes were differenti-
ated from other cells by their light scattering proper-
ties. The phagocytic activity and the intensity of 
oxidative burst inside phagocytes were assessed in 
whole blood environment using a pH-rodo test sys-
tem (Life Technologies). Prior to the measurements, 
erythrocytes were lysed with Q-Prep solutions (Be-
ckman Coulter).
The determination of MCP-1 levels in serum was 
also performed using the FlowCytomix (eBiosci-
ence) test system according to the manufacturer’s 
instructions. The level of complement activity was 
established in a microtest [3] based on the hemolysis 
of sensitized sheep erythrocytes.
Statistics and representation
Statistical analysis was performed in Microsoft Ex-
cel 2010. The same program was used along with 
OriginPro 8.1 for graphical representation of the re-
sults. Due to the small sampling size, a non-paramet-
rical Mann-Whitney test was applied to assess the 
differences between animal groups. The differences 
Fig. 1. Effect of the intraperitoneal and oral substance adminis-
tration upon the level of monocyte chemotactic protein-1
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were considered signifi cant at P < 0.05. The results 
are presented as medians, error bars denote the abso-
lute maximum and minimum.
Results and discussion
1. Effect upon MCP-1 levels
The monocyte chemotactic protein-1 is a major che-
mokine that determines the extent to which a mono-
cyte/macrophage link is involved in the overall im-
mune response [4]. It was shown to be more potent 
than other macrophage chemoattractants [5]. Apart 
from the recruitment of monocytes to the sight of 
infl ammation and stimulation of their proliferation, 
MCP-1 also attracts T-cells, plays a part in the polar-
ization of Th0 lymphocytes into Th1/Th2 subpopu-
lations, and affects the activity of NK- and memory 
T-cells [6]. Most MCP-1 producing cells are also ab-
le to produce IFN and other cytokines. That is why 
after introduction of immunomodulatory substances, 
the changes in this chemokine level were expected. 
Interestingly, however, that in case of S1 a maximum 
MCP-1 level was detected only on the third day after 
the substance administration (Fig. 1), whereas 
tilorone was characterized by a more classical dy-
namics: a peak was observed on the fi rst day of mon-
itoring period, with subsequent gradual decrease. 
These trends were characteristic of both oral- and in-
traperitoneal administration routes. On day X of 
monitoring, the differences between tested and con-
trol animal groups were not signifi cant, therefore the 
data are not provided. 
Up-regulation of MCP-1, observed in the animals 
treated with S1, presumably has a secondary nature, 
taking into account short lifespan of the chemokine 
in vivo and the above described dynamics of its con-
tent. In our experiments on mice [2] it was previ-
ously shown that IFN production reaches maximum 
on the third day after the administration of S1, which 
coincides in time with the peak MCP-1 levels. How-
ever, although interferons, especially IFN-γ, are 
known to induce the MCP-1 synthesis, other factors 
are probably involved in the MCP triggering.
The results, obtained on the animals that received 
i.p. injections, were characterized by a high level of 
variation, which did not allow us to state signifi cant 
differences between the substances starting from the 
third day of monitoring. However, estimating the 
median and maximum MCP-1 levels, detected in the 
animals stimulated with S1 and tilorone, we can as-
sume a more pronounced chemokine potentiation by 
the reference drug. When administered orally, a sig-
nifi cantly lower MCP-1 production was noted for a 
30 mg/kg dose of S1, although the IFN-inducing ef-
fect of this smaller dose is comparable to that of 60 
mg/kg dosage and tilorone (data not provided). 
2. The activity of complement system
The complement system is a collection of soluble 
proteins that circulate in blood in a non-activated 
form, playing a part in both native and adaptive im-
munity. Our understanding of its role in the antiviral 
defense has slightly increased in the recent years. In 
Fig. 2. Complement activity after the intraperitoneal and oral ad-
mi nistration of the substances
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addition to the opsonization and agglutination of vi-
rions, the lysis of virus-infected cells and the chemot-
actic functions, it was shown that complement com-
ponents C3a, C5a and their inactive precursor C3 
also play a role in the activation of cytotoxic T lym-
phocytes [7, 8], NK-, and B-cells [9, 10], as well as 
in the prolongation of their lifespan. The method, 
used by us for assessing the activity of complement 
system, does not allow characterization of the chang-
es in its individual components. However, the ob-
tained results (Fig.2) in general indicate an ability of 
the studied compounds to increase the overall com-
plement hemolytic activity.
The activation effect caused by tilorone in both 
routes of administration was signifi cantly higher 
than that of S1 on the fi rst and third days of monitor-
ing. S1, administered intraperitoneally, did not lead 
to a substantial rise of the complement activity rela-
tive to the control animal group. Moreover, the oral 
application of this substance in 30 mg/kg dose was 
characterized by a lower hemolytic activity com-
pared to tilorone. The dynamics of complement ac-
tivity resembled that of the MCP-1 production: max-
imal levels were detected mostly on the third day of 
observation, except for the oral tilorone application, 
characterized by an earlier peak. At the end of moni-
toring period the differences between all animal 
groups were insignifi cant.
3. Changes in immune
cell counts
The numbers of circulating lymphocytes, mono-
cytes and neutrophils in the blood were established 
on day VII of observation. Both administration 
methods of the reference drug and indoloquinoxa-
line derivative did not lead to signifi cant changes in 
the number of lymphocytes, therefore correspond-
ing data are not provided. Under tilorone infl uence 
neutrophils were signifi cantly increased relative to 
the control (Fig. 3, 4) and in case of the oral admin-
istration – relatively to S1 as well. The increased 
numbers of circulating monocytes were observed 
for both drugs, regardless of administration route. 
However, the oral administration of S1 in 30 mg/kg 
dose did not affect the number of monocytes, or the 
effect lasted less than seven days. It should be not-
ed, that in rodents a great percentage of monocytes 
is deposited in the spleen and can be recruited into 
the blood fl ow more effectively, than in humans 
[11]. The recruitment of neutrophils also took place, 
but had a limited range.
In general, the results obtained resemble a typical 
response to an immune-modulating drug. The chang-
es in absolute lymphocytic counts are rare and occur 
only after serious immunological disturbances, op-
erative interventions or oncological conditions. For 
these reasons we did not expect to reveal them. On 
the other hand, neutrophils and monocytes are much 
Fig. 4. Number of circulating phagocytes on the day VII after 
the oral substance administration
Fig. 3. Number of circulating phagocytes on the day VII after 
the intraperitoneal substance administration
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more labile, mobile cells. An increase in their num-
bers is a common consequence of the cytokine boost. 
Thus, the oral treatment of rats with tilorone, which 
was proved to be more effi cient than S1 at enhancing 
complement activity and MCP-1 levels, logically led 
to higher neutrophil counts. The same dependency 
can be marked between two oral doses of S1: a 
smaller 30 mg/kg dose is characterized by a weaker 
effect upon the MCP-1 and complement system, 
causing a minimal change in cell number. Interest-
ingly, however, i.p. injection of S1 leads to a signifi -
cant increase of monocyte counts relative to the con-
trol, although corresponding treatment did not alter 
the complement activity and only poorly elevated 
the MCP-1 content.
4. Infl uence upon functional
activity of phagocytes
An increase in phagocytic activity of neutrophils 
relative to control was observed in both methods of 
tilorone administration and lasted from the fi rst to 
the seventh day of monitoring period (Fig. 5, 6). A 
similar effect of the tested indoloquinoxaline after 
i.p. injection was less pronounced, and in case of 
oral administration required a bigger dose to mani-
fest. These results correlate with indicators of neu-
trophil metabolic activity: oxidative burst was sig-
nifi cantly intensifi ed on day III and VII after oral 
tilorone administration, whereas for S1 such poten-
tiation was more brief and observed only in case of a 
higher oral dose.
The studied substances mainly did not alter the per-
centage of phagocytizing monocytes. A rise in mono-
cytic absorptive capacity was notable only on the day 
VII of observation in the animals, treated orally with 
tilorone (P < 0,05). In other animal groups the changes 
in phagocytic activity of monocytes were not signifi -
cant, however the substances managed to potentiate 
the intensity of their oxidative burst. In particular, un-
der the 60 mg/kg oral dose of S1, as well as after the 
intraperitoneal injection of this substance, the mono-
cyte metabolic activity was enhanced on the III and 
VII days of observation (Fig. 5, 6). A similar effect of 
the reference drug was notable only on the third day 
for both routes of administration.
Fig. 5. Functional activity of circulating phagocytes after the 
intraperitoneal injection of substances
Note: The left vertical axis corresponds to the cellular absorp-
tion activity, the right Y-axis displays the oxidative activity
Fig. 6. Functional activity of circulating phagocytes after the 
oral substance administration
Note: The left vertical axis corresponds to the cellular absorp-
tion activity, the right Y-axis displays the oxidative activity
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E. coli bacteria, used as an object for phagocytosis 
in this experiment, were not antibody-opsonized. 
That is why the above-described rise of the cellular 
phagocytic activity cannot be linked with the com-
plement system, up-regulated by the studied com-
pounds. However, according to the classical works 
[12, 13] the complement components can modulate 
the oxidative burst intensity without antibody medi-
ation. Obviously, this parameter is even more depen-
dent upon the MCP-1 content. In this respect it 
should be noted that although S1 induced a lower 
MCP-1 production than tilorone, it managed to po-
tentiate the metabolic activity of monocytes as ef-
fectively as the reference drug. The ability of S1 to 
stimulate the oxidative intensity was demonstrated 
earlier on murine peritoneal macrophages [2]. In this 
study S1, administered intraperitoneally, prompted a 
faster and more pronounced tetrazolium reduction by 
macrophages than a greater tilorone dosage. This may 
seem not to correlate with observations of the current 
work, however here a system response of the cells is 
evaluated instead of a local one, and circulating mono-
cytes were studied instead of mature macrophages.
Conclusions 
The application of immuno-stimulating agents with 
the purpose to strengthen the antiviral defense mecha-
nisms as a rule leads to the pluripotent effects. 6-(2-
Morpholin-4-yl-ethyl)-6H-indolo[2,3-b]quinoxaline 
as a low molecular substance is likely to react with the 
membrane and the cytoplasmic pattern recognition 
receptors or even bind to DNA, as was shown for 
some structurally similar indoloquinoxalines [14]. 
Such activity can result in several vectors of intracel-
lular signaling and subsequent effects. The described 
changes in the immunological parameters of the ani-
mals, treated with tilorone and S1, are interconnected 
and altogether indicate the activation of innate immu-
nity. From one sight, this can be considered as a posi-
tive effect, but from the other point of view all the 
studied parameters are referred to as the pro-infl am-
matory markers. A pathological role of complement 
and MCP-chemokines is well recognized in athero-
sclerosis, myocarditis, systemic lupus erythematosus, 
whereas the elevated activity of phagocytes is most 
undesirable during certain pulmonary conditions and 
after organ transplantation [15].
These facts do not imply strictly a negative charac-
ter of the up-regulated immunological parameters. In 
fact, they all remained within- or close to normal 
physiological range. The potentiated hemolytic activ-
ity indicates an elevated content of the non-activated 
complement components, which in the normal condi-
tions are unable to cause a direct physiological action. 
The intensifi cation of oxidative burst is another re-
serve that the organism acquired but does not normal-
ly use. It is a depiction of the increased metabolic re-
sources required to form the reactive oxygen species 
(ROS), which would not be engaged until necessary. 
Therefore, all possibly undesirable biological effects 
that can be mediated by the complement system and 
ROS are not likely to manifest without preliminary 
individual auto-immunological predisposition. MCP-1, 
in turn, is too potent as a chemokine to be left unno-
ticed. Its elevation in case of S1, however, was rela-
tively brief. An increase in monocyte and neutrophil 
counts has a more lasting effect, especially taking into 
account their high absorptive potential.
According to the work [16], human, murine and 
rat monocytes can be divided into two main po pu-
lations:pro-infl ammatory and classical. They pass 
their level of infl ammatory inclination to macrophag-
es, into which they differentiate. In mice all mono-
cytes that are recruited into the blood fl ow from the 
bone marrow are Ly6C+ (analog of human Cd14+ 
CD16+ cells), demonstrating the secretion of ROS, 
TNFα, nitric oxide, IL-1β, large amounts of type 1 
interferon and high phagocytic capacity. The expres-
sion of Ly6C+ later diminishes, turning cells into 
classical Ly6C- monocytes with an anti-infl ammato-
ry cytokine profi le [17]. The stimulatory signals, 
caused by S1 and tilorone, can prevent this process, 
causing a long-time infl ammatory predisposition in 
some percent of phagocytes. This consequence to 
certain extent is inevitable for all medications that 
induce the endogenous cytokine production. Never-
theless, potential adverse effects in patients with al-
lergic and immunological disorders should be taken 
into account during the subsequent pre-clinical and 
clinical testing of S1.
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An important observation is that the different dos-
es and application routs of S1 can lead to a stronger 
or weaker elevation of the infl ammatory markers. In 
particular, a lower oral dose – 30 mg/kg, which in 
our previous experiment induced the prolonged IFN 
production, was characterized by minimal infl uence 
upon the numbers and function of phagocytizing 
cells in blood, the complement activity and MCP-1 
content. It means that the tested indoloquinoxaline 
can potentiate the antiviral immunity with minimal 
infl ammatory effects.
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Вплив 6-(2-морфолін-4-іл-етил)-6H-індоло
[2,3-b]хіноксаліна на біомаркери запалення 
Г. В. Антонович, Н. М. Жолобак,
М. О. Шибінська, М. Я. Співак 
Мета. Дослідити вплив 6-(2-морфолін-4-іл-етил)-6H-індоло 
[2,3-b]хіноксаліна (антивірусної сполуки з інтерферон-ін ду-
куючою дією) на про-запальний статус лабораторних щурів. 
Методи. Концентрація MCP-1, кількість лейкоцитів в кро ві 
та функціональна активність фагоцитів визначали цитофлю-
ориметричними методами. Активність системи комплемен-
ту оцінювалась в мікротесті на основі гемолізу сенситизова-
них еритроцитів. Результати. Застосування перорального 
та парентерального способу введення сполук супроводжу-
валось збільшенням кількості моноцитів, потенціонуванням 
метаболічного резерву фагоцитуючих клітин, під вищенням 
вмісту MCP-1 і компонентів комплементу в сироватці крові. 
Після введення 6-(2-морфолін-4-іл-етил)-6H-індоло[2,3-b]
хіноксаліну достовірного збільшення кількості циркулюю-
чих нейтрофілів або їх фагоцитарної активності не спосте-
рігалось, в той час як рівні MCP-1 і компонентів комплемен-
ту були значно нижчими, ніж у препарату порівняння – ти-
лорону. Висновки. ІХоча обидві сполуки є індукторами ІФН 
з плюрипотентною імуностимулюючою дією, тестоване по-
хідне призводило до менш вираженого підвищення актив-
ності комплементу, нижчого вмісту MCP-1 та кількісті ней-
трофілів. Даний факт свідчить на користь того, що застосу-
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вання 6-(2-морфолін-4-іл-етил)-6H-індоло[2,3-b]хіноксаліну 
для посилення неспецифічного антивірусного імунітету су-
проводжуватиметься нижчим ризиком розвитку побічних 
аутоімунологічних реакцій 
Ключов і  слова: 6H-індоло[2,3-b]хіноксалін, запалення, 
інтерферон, MCP-1, комплемент.
Влияние 6-(2-морфолин-4-ил-этил)-6H-индоло
[2,3-b]хиноксалина на биомаркеры воспаления 
Г. В. Антонович, Н. М. Жолобак,
М. О. Шибинская, Н. Я. Спивак
Цель. Изучить влияние 6-(2-морфолин-4-ил-этил)-6H-ин до -
ло[2,3-b]хиноксалина (антивирусного соединения с интер-
ферон-индуцирующим действием) на про-воспалительный 
статус лабораторных крыс. Методы. Концентрация MCP-1, 
количество лейкоцитов в крови и функциональная актив-
ность фагоцитов определялись цитофлюориметрическими 
методами. Активность системы компле мента оценивали в 
микротесте, основанном на гемолизе сенситизированных 
эритроцитов. Результаты. Как пероральный, так и паренте-
ральный способы введения соединений приводили к увели-
чению количества моноцитов, потенционированию метабо-
лического резерва фагоцитирующих клеток, повышению со-
держания MCP-1 и компонентов комплемента в сыворотке 
крови. После введения 6-(2-морфолин-4-ил-этил)-6H-ин-
доло[2,3-b]хиноксалина достоверного увеличения числен-
ности циркулирующих нейтрофилов либо их фагоцитарной 
активности не наблюдалось, в то время как уровни MCP-1 и 
компонентов комплемента были значительно ниже, чем у 
препарата сравнения – тилорона. Выводы. Хотя оба соеди-
нения представляют собой индукторы ИФН с плюрипотен-
тным иммуностимулирующим действием, тестируемое про-
изводное приводило к менее выраженному повышению ак-
тивности комплемента, меньшему содержанию MCP-1 и ко-
личеству нейтрофилов. Данный факт свидетельствует о том, 
что применение 6-(2-морфолин-4-ил-этил)-6H-индоло[2,3-b]
хиноксалина для усиления неспецифического противови-
русного иммунитета будет нести более низкие риски разви-
тия побочных аутоиммунологических реакций. 
Ключевые  слова: 6H-индоло[2,3-b]хиноксалины, вос па-
ление, интерферон, MCP-1, комплемент.
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